French drug manufacturer Sanofi-Aventis reported sales of €7.39bn in the fourth quarter of 2010, up 0.5% on last year’s figures.

Exchange rate movements had a favourable effect, amounting to 6.4%, with constant exchange rates amounting to a net sales decrease of 5.9%. Excluding changes in structure, fourth quarter sales declined 7.1%, 2.4% when excluding pandemic influenza sales.

Net sales in 2010 were 3.7% higher on a reported basis at €30.38bn, while exchange rate movements had a 4.5% favourable effect, reflecting on the appreciation of the US, Australian and Canadian dollars, Brazilian Real and Japanese Yen against the Euro.

Sanofi-Aventis CEO Christopher Viehbacher said, “We have delivered another year of EPS growth due to excellent performance of our growth platforms, which now accounts for 54% of sales, and tight cost control.”